145 related articles for article (PubMed ID: 33767486)
1. Nationwide dispensing of cardioprotective medications during the first year following acute coronary syndrome (ANZACS-QI 56).
Butchard M; Kerr AJ; Grey C; Wu B; Hider P
N Z Med J; 2021 Mar; 134(1531):36-54. PubMed ID: 33767486
[TBL] [Abstract][Full Text] [Related]
2. Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34).
Chan D; Doughty RN; Lund M; Lee M; Kerr AJ
Heart Lung Circ; 2020 Sep; 29(9):1386-1396. PubMed ID: 32423781
[TBL] [Abstract][Full Text] [Related]
3. Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors.
Gunnell AS; Hung J; Knuiman MW; Nedkoff L; Gillies M; Geelhoed E; Hobbs MS; Katzenellenbogen JM; Rankin JM; Ortiz M; Briffa TG; Sanfilippo FM
Cardiovasc Ther; 2016 Dec; 34(6):423-430. PubMed ID: 27489053
[TBL] [Abstract][Full Text] [Related]
4. Utilisation and maintenance of high-intensity statins following acute coronary syndrome and coronary angiography: opportunities to improve care (ANZACS-QI 26).
Kerr AJ; Mitnala S; Lee M; White HD
N Z Med J; 2020 Mar; 133(1511):21-40. PubMed ID: 32161419
[TBL] [Abstract][Full Text] [Related]
5. Heart failure clinics improve use of evidence-based heart failure therapies in patients with reduced ejection fraction following acute coronary syndrome (ANZACS-QI 48).
Chan D; Doughty RN; Mazengarb J; McLachlan A; Kerr AJ
N Z Med J; 2020 Jun; 133(1516):58-71. PubMed ID: 32525862
[TBL] [Abstract][Full Text] [Related]
6. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study.
Pereira M; Araújo C; Dias P; Lunet N; Subirana I; Marrugat J; Capewell S; Bennett K; Azevedo A
Eur J Prev Cardiol; 2014 Nov; 21(11):1401-8. PubMed ID: 23787795
[TBL] [Abstract][Full Text] [Related]
7. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
8. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
9. Demographic differences in the initiation and maintenance of statins in the first year post ACS in New Zealand: a data linkage study (ANZACS-QI 57).
Muniandy A; Lee M; Grey C; Ferrier K; Kerr AJ
N Z Med J; 2021 Apr; 134(1534):31-45. PubMed ID: 33927436
[TBL] [Abstract][Full Text] [Related]
10. Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice.
Kassab YW; Hassan Y; Aziz NA; Akram H; Ismail O
J Eval Clin Pract; 2013 Aug; 19(4):658-63. PubMed ID: 22845427
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial.
Ho PM; Lambert-Kerzner A; Carey EP; Fahdi IE; Bryson CL; Melnyk SD; Bosworth HB; Radcliff T; Davis R; Mun H; Weaver J; Barnett C; Barón A; Del Giacco EJ
JAMA Intern Med; 2014 Feb; 174(2):186-93. PubMed ID: 24247275
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of statin use over 3 years following acute coronary syndromes: a national data linkage study (ANZACS-QI-2).
Grey C; Jackson R; Wells S; Thornley S; Marshall R; Crengle S; Harrison J; Riddell T; Kerr A
Heart; 2014 May; 100(10):770-4. PubMed ID: 24436219
[TBL] [Abstract][Full Text] [Related]
13. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O
J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979
[TBL] [Abstract][Full Text] [Related]
14. Management and Long-Term Outcome of Acute Coronary Syndrome Patients Presenting with Heart Failure in a Contemporary New Zealand Cohort (ANZACS-QI 4).
Kueh SH; Devlin G; Lee M; Doughty RN; Kerr AJ
Heart Lung Circ; 2016 Aug; 25(8):837-46. PubMed ID: 27132622
[TBL] [Abstract][Full Text] [Related]
15. High level of capture of coronary intervention and associated acute coronary syndromes in the all New Zealand acute coronary syndrome quality improvement cardiac registry and excellent agreement with national administrative datasets (ANZACS-QI 25).
Kerr AJ; Lee M; Jiang Y; Grey C; Wells S; Williams M; Jackson R; Poppe K
N Z Med J; 2019 Mar; 132(1492):19-29. PubMed ID: 30921308
[TBL] [Abstract][Full Text] [Related]
16. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.
Yan AT; Yan RT; Tan M; Huynh T; Soghrati K; Brunner LJ; DeYoung P; Fitchett DH; Langer A; Goodman SG;
Am Heart J; 2007 Dec; 154(6):1108-15. PubMed ID: 18035083
[TBL] [Abstract][Full Text] [Related]
17. Initiation and maintenance of statins and aspirin after acute coronary syndromes (ANZACS-QI 11).
Kerr AJ; Turaga M; Grey C; Lee M; McLachlan A; Devlin G
J Prim Health Care; 2016 Sep; 8(3):238-249. PubMed ID: 29530207
[TBL] [Abstract][Full Text] [Related]
18. Optimizing prevention and guideline-concordant care in Montenegro.
Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
[TBL] [Abstract][Full Text] [Related]
19. Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24.
Kasargod C; Devlin G; Lee M; White HD; Kerr AJ
Heart Lung Circ; 2020 Jun; 29(6):824-834. PubMed ID: 31255479
[TBL] [Abstract][Full Text] [Related]
20. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1).
Kerr A; Exeter D; Hanham G; Grey C; Zhao J; Riddell T; Lee M; Jackson R; Wells S
N Z Med J; 2014 Aug; 127(1400):39-69. PubMed ID: 25145366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
